SANDOZ ALENDRONATE/CHOLECALCIFEROL TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

ALENDRONIC ACID (ALENDRONATE SODIUM TRIHYDRATE); VITAMIN D3 (CHOLECALCIFEROL)

Disponibbli minn:

SANDOZ CANADA INCORPORATED

Kodiċi ATC:

M05BB03

INN (Isem Internazzjonali):

ALENDRONIC ACID AND CHOLECALCIFEROL

Dożaġġ:

70MG; 5600UNIT

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

ALENDRONIC ACID (ALENDRONATE SODIUM TRIHYDRATE) 70MG; VITAMIN D3 (CHOLECALCIFEROL) 5600UNIT

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

4

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

VITAMIN D

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0251575002; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2023-07-28

Karatteristiċi tal-prodott

_ _
_Sandoz Alendronate/Cholecalciferol _
_Page 1 of 46_
PRODUCT MONOGRAPH
Pr
SANDOZ ALENDRONATE/CHOLECALCIFEROL
alendronate sodium/cholecalciferol tablets
70 mg alendronate (as alendronate sodium) + 140 mcg cholecalciferol
(5600 IU vitamin D
3
)
Bone Metabolism Regulator and Vitamin D
Sandoz Canada Inc.
145 Jules-Léger
Boucherville, Québec
J4B 7K8
Date of Revision:
July 18, 2017
Submission Control No: 206959
_ _
_Sandoz Alendronate/Cholecalciferol. _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
15
OVERDOSAGE
................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 17
STORAGE AND STABILITY
.........................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 23
PART II: SCIENTIFIC INFORMATION
..............................................................................
24
PHARMACEUTICAL INFORMATION
.........................................................................
24
CLINICAL TRIALS
.........